Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 64, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2022.128636
Keywords
Wee1; CDK1; Checkpoint inhibition; PROTAC; Targeted degradation; VHL; Cereblon
Categories
Funding
- North West Cancer Research [LFSL2018-23]
Ask authors/readers for more resources
The Ser/Thr protein kinase Wee1 plays a regulatory role in DNA damage by phosphorylating CDK1. The selective inhibitor AZD1775 has off target effects on other protein kinases. This study describes the synthesis and evaluation of Wee1-degrading PROTACs with different linkers.
The Ser/Thr protein kinase Wee1 plays a regulatory role at the G(2)/M checkpoint by phosphorylating CDK1 when DNA is damaged to allow time for DNA to repair, disruption of which is a key approach to sensitise cancer cells to DNA-damaging therapies. The main selective inhibitor for Wee1 undergoing development in clinical trials, AZD1775, however, has been shown to have off target effects towards other protein kinases with similar potency. Here we describe the synthesis and assessment of a series of Wee1-degrading PROTACs using AZD1775 linked to either the VHL ligand VH032 or to the CRBN ligand pomalidomide using different types and lengths of linkers. The conversion of AZD1775 into a PROTAC induces selective Wee1 degradation for compounds of both series depending on the nature of the linker.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available